Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL27710851 | 0.96 | ALDH1A1 (0.46) | ALDH1A1TTRLMNASMN1; SMN2PKM | |
| Dioxane SCHEMBL8207440 | 0.96 | ALDH1A1 (0.46) | ALDH1A1TTRLMNASMN1; SMN2PKM | |
| Isopropyl Alcohol SCHEMBL3292218 | 0.96 | — | — | |
| Dioxane SCHEMBL2057757 | 0.93 | TTR (0.43) | ALDH1A1TTRLMNASMN1; SMN2PKM | |
| Oxirane SCHEMBL27595280 | 0.87 | — | — | |
| Isopropyl Alcohol SCHEMBL5228428 | 0.85 | — | — | |
| Tetrahydrofuran SCHEMBL154168 | 0.85 | — | — | |
| Oxirane SCHEMBL7653670 | 0.83 | — | — | |
| Isopropyl Alcohol SCHEMBL9004332 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TTRLMNASMN1; SMN2PKM | |
| Tetrahydrofuran SCHEMBL16738662 | 0.82 | ALDH1A1 (0.53) | ALDH1A1TTRLMNASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2021-06-24 | — | — | US | claimed |
| EP-3808745-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-04-21 | — | — | EP | claimed |
| CN-112090117-A | Preparation method of oil-water separation material with magnetic response | 南昌航空大学 | 2020-12-18 | — | — | CN | claimed |
| CN-111819178-A | Crystal form of pyrazolo heteroaryl derivative hydrochloride and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-110483813-A | A kind of preparation method of room temperature photo-thermal selfreparing hydrogel | UNIV NANCHANG HANGKONG | 2019-11-22 | — | — | CN | claimed |
| WO-2015058141-A1 | NUCLEOBASE-CONTAINING MONOMERS AND COPOLYMERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
| JP-5310860-A | — | — | None | — | — | JP | disclosed |
| CN-116041328-A | Process for preparing CDK4/6 kinase inhibitor compounds | 轩竹生物科技股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-111819178-B | Crystal form of pyrazolo heteroaryl derivative hydrochloride and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3645484-B1 | METHOD FOR PREPARATION OF ALKYLATED OR FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HETEROGENEOUS COBALT CATALYSIS | LONZA SOLUTIONS AG (CH) | 2021-11-10 | — | — | EP | disclosed |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2021-06-24 | — | — | US | disclosed |
| EP-3808745-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-10968187-B2 | Method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by heterogeneous cobalt catalysis | LONZA SOLUTIONS AG (CH) | 2021-04-06 | — | — | US | disclosed |
| EP-0350014-A2 | Volume phase type hologram and method of manufacture thereof | CANON KABUSHIKI KAISHA (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4256592-A | METAL SALTS OF HYDROCARBYL OXAZOLINE PHOSPHORODITHIOIC ACIDS EFFECTIVE IN REDUCING FRICTION AND WEAR IN INTERNAL COMBUSTION ENGINES | MOBIL OIL CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| US-4053312-A | O-SULFONAMIDONAPHTHOL DIFFUSIBLE DYE IMAGE PROVIDING COMPOUNDS | EASTMAN KODAK COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-4006141-A | MICROBIOCIDE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-02-01 | — | — | US | disclosed |
| US-3989832-A | Combating bacteria with nitroimidazolyl-triazolo-pyridiazine compounds | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-11-02 | — | — | US | disclosed |
| US-3962242-A | BACTERIOSTATS, URINARY TRACT INFECTIONS | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-06-08 | — | — | US | disclosed |
| US-3944385-A | MONOPERSULFURIC ACID SALT, EPOXIDE REACTION PRODUCT, FATTY AMINE ETHYLENE OXIDE ADDUCT | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968187-B2 | Method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by heterogeneous cobalt catalysis | ABL1, CAT, MYC | ALDH1A1 2080/4885TTR 3896/4885LMNA 3178/4885 |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | CYP2F1, CYP7A1, CYP11B2 | ALDH1A1 1161/4885TTR 1664/4885LMNA 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.